Sugi Predict

Sugi Predict / Compounds / SCHEMBL3717192

SCHEMBL3717192

SCHEMBL3717192

CC(=O)N[C@H]1[C@H](OCCN)O[C@H](CO)[C@@H](O)[C@@H]1O

nearest known ligand 0.71

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.71
▸ ALDH1A1 P00352 2/20 0.60
▸ THRB P10828 1/20 0.60
▸ LGALS8 O00214 1/20 0.56
▸ LGALS3 P17931 1/20 0.56
▸ LGALS4 P56470 1/20 0.56
▸ MEN1 O00255 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ CA1 P00915 2/20 0.51
▸ CA2 P00918 2/20 0.51
▸ CA9 Q16790 2/20 0.51
▸ CD69 Q07108 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ IGF2R P11717 1/20 0.48
▸ B4GALT1 P15291 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31536873 1.00 MAPK1 (0.71) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL36783651 1.00 MAPK1 (0.71) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL14345965 1.00 MAPK1 (0.71) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL13702251 1.00 MAPK1 (0.71) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL4290431 1.00 MAPK1 (0.71) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL19903782 1.00 MAPK1 (0.71) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL22576748 1.00 MAPK1 (0.71) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL21940522 1.00 MAPK1 (0.71) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL21018974 1.00 MAPK1 (0.71) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL15489113 1.00 MAPK1 (0.71) MAPK1ALDH1A1THRBLGALS8LGALS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122055374-A Lipid compounds and compositions for tissue-specific delivery of active substances 韩国生命工学研究院 2026-05-15 — — CN disclosed
WO-2025083657-A1 LIPID COMPOUND AND COMPOSITION FOR TISSUE-SPECIFIC DELIVERY OF ACTIVE SUBSTANCE 한국생명공학연구원 2025-04-24 — — WO disclosed
US-11820805-B2 Conjugate based systems for controlled insulin delivery MERCK SHARP & DOHME LLC (US) 2023-11-21 — — US disclosed
US-11820805-B2 Conjugate based systems for controlled insulin delivery MERCK SHARP & DOHME LLC (US) 2023-11-21 — — US disclosed
US-11820805-B2 Conjugate based systems for controlled insulin delivery MERCK SHARP & DOHME LLC (US) 2023-11-21 — — US disclosed
CN-109071607-B Vancomycin derivatives, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2022-09-27 — — CN disclosed
CN-113943330-A Sugar-containing structure compound, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2022-01-18 — — CN disclosed
US-20210198339-A1 CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY MERCK SHARP & DOHME CORP. (US) 2021-07-01 — — US disclosed
US-20210198339-A1 CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY MERCK SHARP & DOHME CORP. (US) 2021-07-01 — — US disclosed
US-20210177981-A1 CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY MERCK SHARP & DOHME CORP. (US) 2021-06-17 — — US disclosed
US-20110281792-A1 BINDING-SITE MODIFIED LECTINS AND USES THEREOF SMARTCELLS, INC. 2011-11-17 — — US disclosed
US-20110275560-A1 SYNTHETIC CONJUGATES AND USES THEREOF SMARTCELLS, INC. 2011-11-10 — — US disclosed
WO-2010107519-A1 TERMINALLY-FUNCTIONALIZED CONJUGATES AND USES THEREOF SMARTCELLS, INC. (US) 2010-09-23 — — WO disclosed
WO-2010088286-A1 SYNTHETIC CONJUGATES AND USES THEREOF SMARTCELLS, INC. (US) 2010-08-05 — — WO disclosed
WO-2010088276-A2 POLYNUCLEOTIDE APTAMER-BASED CROSS -LINKED MATERIALS AND USES THEREOF SMARTCELLS, INC. (US) 2010-08-05 — — WO disclosed
WO-2010088261-A1 BINDING-SITE MODIFIED LECTINS AND USES THEREOF SMARTCELLS, INC. (US) 2010-08-05 — — WO disclosed
WO-2010088300-A1 CRYSTALLINE INSULIN-CONJUGATES SMARTCELLS, INC. (US) 2010-08-05 — — WO disclosed
WO-2010088268-A1 EXOGENOUSLY TRIGGERED CONTROLLED RELEASE MATERIALS AND USES THEREOF SMARTCELLS, INC. (US) 2010-08-05 — — WO disclosed
WO-2010088294-A1 CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY SMARTCELLS, INC. (US) 2010-08-05 — — WO disclosed
WO-2010088294-A1 CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY SMARTCELLS, INC. (US) 2010-08-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275560-A1 SYNTHETIC CONJUGATES AND USES THEREOF SLC2A4, SLC2A8, CD44 MAPK1 3352/4885ALDH1A1 2321/4885THRB 3419/4885
US-20210177981-A1 CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY GPR119, INSR, IGF1R MAPK1 4482/4885ALDH1A1 1292/4885THRB 1264/4885
US-11820805-B2 Conjugate based systems for controlled insulin delivery GPR119, INSR, IGF1R MAPK1 4342/4885ALDH1A1 1357/4885THRB 1643/4885
US-20210198339-A1 CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY GPR119, INSR, IGF1R MAPK1 4342/4885ALDH1A1 1357/4885THRB 1643/4885
US-20110281792-A1 BINDING-SITE MODIFIED LECTINS AND USES THEREOF SIGLEC7, SIGLEC9, LGALS3BP MAPK1 3742/4885ALDH1A1 1909/4885THRB 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback